ceo success balanc sheet reload
posit strength solid
view outperform-r high-qual beat as-
expect outlook partli overshadow unexpect
septemb ceo transit common/convert prefer stock
issuanc reload balanc sheet follow bil cytiva
acquisit take ceo success seamless
balanc sheet reload signal look play offens
ceo transit stock offer announc modestli overshadow
solid result outlook danah oper beat as-
expect outlook bookend two major announc
name ceo transit tom joyc rainer blair bil
common prefer stock issuanc regard ceo transit
bottom line expect smooth leadership hand-off
rainer blair logic candid given directli
overse life scienc mix recent acquisit
cytiva pall industri contact univers prais mr blair
leadership talent see report ceo transit
stock issuanc dilut share-count leverag
lower quarter-end due cytiva acquisit
closer estim overal believ make
move posit strength evidenc
oper beat driven upsid diagnost includ cepheid
organ growth due test-kit demand forecast
organ revenu declin inclus cytiva part
organ result look rel contain includ bp
tailwind covid-rel demand lower cash ep
estim rais price target
biggest surpris unexpect announc conced
leadership transit time bit unexpect given mr joyc
ceo six year midst unpreced
econom recess combin stock issuanc news
disclos soon earn call end announc like
overshadow otherwis solid oper result lead
stock bp under-perform vs peer may
implications/read-across pocket covid-rel demand growth
amidst broader econom downturn danah biom busi
cepheid beckman cytiva pallar lever differ way
covid-rel demand expect persist medium-
term contribut bp organ growth tailwind
within multi-industri coverag also seen pocket
healthcare-rel growth
valu usd unless otherwis note
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
defens safe leverag recur revenu
test-kit demand global economi
precipic spiral recess believ
investor move qualiti curv toward
defens safe haven weather loom
macro headwind recur revenu mix
portfolio attribut healthcar vertic
long view break glass case
emerg invest portfolio well-
posit outperform econom downturn
financi crisi
industri recess importantli danah cepheid
busi combin revenu receiv us
regulatori approv test-kit product detect
coronaviru ramp product meet
soar demand
best-in-class multi-industri name metric
hold much-covet posit among higher-
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
acquir biopharma busi bil
complet acquisit biopharma
busi bil impli reason deal multipl
ev/ebitda deal expect produc mil
cost save ge biopharma renam cytiva
lead provid instrument consum softwar
support research discoveri process develop
manufactur workflow biopharmaceut drug
given expens price-tag major integr
stumbl cytiva pall cepheid would damag
faith investor disciplin
pandem busi disrupt remain on-going
bloomberg capit market estim upside/downside/target
given loom econom downturn market rotat
toward higher-qu defens safe haven
assum share trade premium
previous target group multipl
price-to-earnings cash ep high-end
histor rel rang reflect compani defens
risk-off portfolio includ recur revenu
believ favor macro downturn underpin
price target support outperform rate
market enter risk-off environ danah
deliv upsid synergies/accret target
believ stock may abl re-rat beyond high-
end rel rang premium
target group multipl also see potenti upsid
ep reach level includ acceler
organ growth end market improv would
carri execut risk misstep
 integr could weigh stock addit
high-qual defens name would lag
market enter prolong risk-on environ favor
cyclic higher-beta stock could see price-to-earnings contract
premium target group multipl
also risk end market slowdown result
ep closer valuat
takeaway result
note
organ growth
busi prior
brace organ revenu declin includ bp covid-rel
demand recal alreadi suspend full-year guidanc due
heighten uncertainti durat sever disrupt
compani forecast organ revenu declin includ
organ growth tailwind cytiva recent acquir busi
busi prior year comp alreadi organ result addit danah
estim strong demand relat product cepheid radiomet
contribut bp organ growth tailwind impli rest portfolio
said manag note includ potenti upsid
demand beckman new covid-rel serolog offer final expect
environment appli solut fall toward lower-end rang mid-
high-teen organ revenu declin given buoy covid-rel
tailwind lower cash ep estim
april organ revenu y/i comp get harder may june danah april
organ revenu actual y/i modestli better manag
expect driven upsid cepheid cytiva howev caution
april total revenu y/i comp headwind becom
tougher roughli bp may june despit april strength
still brace organ revenu declin although covid-rel
pharma biotech busi remain strong see weak busi
like beckman diagnost leica biosystem depend patient
volum pressur declin elect procedur due pandem
geographi north america western europ begin stabil
region gradual reopen china alreadi improv april
project decrement margin diagnost
expect decrement margin roughli diagnost due
fx-relat headwind note among compani multi-
industri coverag announc broad-bas cost-out program either temporari
structur said compani execut roughli million cost action everi
year part normal cours busi db oper playbook expect
action acceler respons volum declin
announc billion offer common stock mandatori convert
prefer stock immedi earn call announc concurr
offer billion share common stock billion share mandatori
convert prefer stock mcp includ potenti green-sho offer
combin net proce would roughli billion capit alloc gener
corpor purpos includ futur debt pay-down estim common
stock mcp includ green-sho would equat roughli million share
roughli total sharecount
danah busi frontlin fight pandem mani
busi frontlin healthcar commun effort combat
spread harm pandem offer provid critic diagnost
test capabl well resourc discoveri product treatment
vaccin busi lever covid-rel demand includ
cepheid rapid molecular test detect march cepheid launch
xpert xpress first rapid molecular test detect
coronaviru within roughli minut best-in-class test design oper across
cepheid global instal base autom genexpert system includ
us compani alreadi ship roughli million test cartridg far
work expand product capac ramp roughli million test per
quarter exceed initi expect remind cepheid contribut
billion total revenu mix diagnost mix
idt primer probe kit key compon test integr dna
technolog ramp product primer probe kit key
compon test detect coronaviru date
alreadi ship enough kit enabl million diagnost test enough
capac suppli roughli million per week estim contribut roughli
mix life scienc mix
beckman coulter develop assay identifi antibodi march
beckman coulter announc develop assay identifi antibodi covid-
would play critic role expand understand immun
viru beckman launch one assay mid-may form new
access igg serolog test plan ramp product million test
may million test per month end june assay compat
beckman global instal base immunoassay analyz
pall cytiva support product vaccin therapeut candid
pall filtrat solut design bioproduct process multipl lead
vaccin candid cytiva provid resin help numer vaccin program
scale-up product volum vaccin therapeut candid
market today pall cytiva work major
capac expect busi play critic role
pursuit test treatment prevent ultim cure
cash ep beat recent lower estim consensu
organ growth in-lin pre-announce report adjust
cash ep recent lower estim consensu
organ revenu growth total revenu growth in-lin
compani pre-announce month januari februari
solid follow sever downturn march near end quarter notabl
diagnost organ driven cepheid thank demand flu
test-kit addit cytiva achiev roughli organ growth adjust
oper margin expand bp y/i outpac estim bp
increment margin solid quarter overal oper line
estim upsid entir attribut diagnost segment
line lower net interest incom shave penni final free cash flow convers
roughli in-lin histor averag convers
revenu develop
market high-
single-digit high
growth market
high-single-digit led
china
revenu sharpli
deterior
organ declin
inclus cytiva
manag state
wait
cytiva acquisit close
announc
also believ
regulatori reason
leadership transit
made public
announc may
note organ revenu growth estim sector actual
upcom catalyst point monitor
expect smooth ceo transit tom joyc rainer blair effect septemb
may announc evp rainer blair age would succeed tom
joyc age presid ceo member board director effect
emphat bottom line expect smooth leadership transit view glue
hold entir compani togeth vaunt organiz cultur built
around proprietari danah busi system db time-test proprietari oper
model enabl compani seamlessli handl intern senior manag transit
given everi member leadership team run exact playbook
anticip also case mr blair ascent ceo histori guid
recal skip beat former-ceo larri one
architect db oper model left compani year ceo work
year mr joyc look transit retir howev
stay senior advisor compani februari ensur
rainer blair logic successor ceo role highlight industri
contact unanim prais mr blair leadership talent
view mr blair age logic candid brass ring given
run segment revenu execut vice presid
mr blair join presid north america europ videojet
promot presid sciex mr blair later promot group
execut execut vice presid addit mr blair led
recent mileston acquisit pall cytiva indic well-vers
compani differenti playbook
integr billion acquisit ge biopharma rebrand cytiva
complet billion acquisit biopharma busi impli
reason deal multipl price/sal ev/ebitda busi
rebrand cytiva manag stand-alone oper compani within life
scienc segment busi leader instrument softwar consum
support research process develop manufactur discoveri workflow
biopharmaceut drug deliv mid-teen organ growth ebitda
margin annual free cash flow roughli billion look ahead expect
cytiva organ growth deceler low-double-digit benefit
organ growthshad area multi-industri sector averagenot restatedfor spin larger water player
would like interest
acquir danah
outright believ
pricey valuat
make spin like
secular driver across biolog drug develop cell gene therapi demand
high growth market product line includ downstream bioprocess revenu
mix upstream bioprocess regard synergi acquisit
expect produc million annual cost save year-thre along potenti
revenu synergi though manag yet size opportun
believ could eventu pursu spin-out water qualiti follow
close ge biopharma acquisit revenu mix attribut
life scienc diagnost segment addit recent major acquisit
space includ ge biopharma cepheid
qualiti product id platform revenu increasingli look like non-core
outlier within portfolio view thu believ eventu opt
divest best-in-class water qualiti platform either stand-alone busi pair
product id like one reason chose spotlight water qualiti
analyst meet see recap given scarciti invest water
pure-play market believ publicli trade water qualiti entiti would
tremend appeal investor term time expect wait
stabil market econom backdrop pursu spin water qualiti
order ensur success market debut
water qualiti market leader high-end water technolog billion
annual revenu mix water qualiti market leader water
test/analyt hach brand ultraviolet uv disinfect trojan
technolog brand chemic disinfect chemtreat brand among
leader membran filtrat pall brand busi sit
higher-end water technolog continuum command higher valuat
barrier entri margin growth potenti recur revenu mix water
qualiti expect manag sustain mid-single-digit organ revenu growth
one profit platform portfolio ebitda
margin vs compani averag manag estim total
address market size billion impli roughli share
long-term market growth driver includ enhanc regul water scarciti
invest sustain busi plan outpac market use share
gain new product develop expans high growth market
rel price-to-earnings trade near high-end rel rang share
current trade price-to-earnings premium multi-industri sector cash ep
believ stock trade premium target group multipl
high-end histor rel rang impli price target
support outperform rate
ev/ebitda premium ev/ebitda basi trade
estim repres rel premium multi-industri peer group averag
share price trade premium weight averag price-to-earnings
publicly-trad peer cash ep believ deserv
premium reflect market leadership db toolkit
price assum after-tax cost capit beta annual sale growth
termin growth rate
compani report capit market estim
millionsmarjunsepdecmar-ajunsepdecmarjunsepdecseg revenueslif dentalenvironment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens incomerest dental discontinu exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper restat dental discontin oper electr equip multi-industri
given loom econom downturn market rotat toward higher-qu defens
safe haven assum share trade premium
target group multipl price-to-earnings cash ep high-end histor
rel rang reflect compani defens risk-off portfolio includ recur
revenu believ favor macro downturn underpin
price target support outperform rate
risk rate price target
coronaviru pandem busi disrupt pandem could caus
oper result fall short expect
acquisit one acquisit compani sector alway risk
overpay experienc integr difficulti major deal believ
integr stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
three segment life scienc diagnost environment appli solut
also oper differenti framework growth lean leadership tool process
known danah busi system across aspect oper includ product
develop qualiti control global sourc sale market
modestli headquart washington employ peopl global
